Evaluation of the efficacy of ADHD treatment with the use of EEG-biofeedback method in comparison to methylphenidate
More details
Hide details
Neuromed – Centre of Neuropsychiatry, Wroclaw, Poland
Department of Psychiatry, Medical University of Wroclaw, Poland
Tomasz Adamowski   

Department of Psychiatry, Medical University of Wroclaw, Poland, Wyb. L. Pasteura 10, 50-367 Wrocław, Poland
Submission date: 2015-09-21
Final revision date: 2015-11-07
Acceptance date: 2015-11-07
Publication date: 2016-05-01
Arch Psych Psych 2015;17(4):32–38
Aim of the study:
The purpose of the study was to evaluate the efficacy of the EEG-biofeedback (NF) method in ADHD treatment in each of the three basic DSM-IV-TR clinical types.

Subject or material and methods:
85 patients aged 6 to 14 treated in an outpatient department and a day-care department (S) were qualified for the EEG-biofeedback therapy, whereas the control group consisted of 30 patients (C) who were treated with methylphenidate. For the purposes of evaluating the treatment efficacy, a structured interview on the presence of the ADHD symptoms was conducted. The S group patients participated in 20 NF therapy sessions throughout a six-month period. An analysis of electrophysiological parameters of EEG was additionally performed in group S - Th/SMR and Th/Beta ratios in C3 and C4 channels at three points in time (at the beginning, during the course of and at the end of the EEG-biofeedback therapy).

Both types of S and C group therapies significantly reduce (p < 0.01) the number of attention deficit, hyperactivity and impulsiveness symptoms in subgroups with attention deficit prevalence and mixed type. In all ADHD types, significant decrease in values of the examined Th/SMR and Th/Beta ratios was noted between the sessions 1 and 10.

The NF method proved similarly effective as methylphenidate in reducing the number of symptoms, both in the type with prevalence of attention deficit and in the mixed type.

The results of the study are promising, since the EEG-biofeedback therapy was similarly effective as methylphenidate in reducing the aggravation of ADHD symptoms.